These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 12902411)

  • 1. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
    Guay C; Lépine M; Verreault J; Bénard F
    J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
    Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
    J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.
    Jerusalem G; Beguin Y; Fassotte MF; Belhocine T; Hustinx R; Rigo P; Fillet G
    Ann Oncol; 2003 Jan; 14(1):123-30. PubMed ID: 12488304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
    Spaepen K; Stroobants S; Dupont P; Thomas J; Vandenberghe P; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    Br J Haematol; 2001 Nov; 115(2):272-8. PubMed ID: 11703321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma.
    Dittmann H; Sokler M; Kollmannsberger C; Dohmen BM; Baumann C; Kopp A; Bares R; Claussen CD; Kanz L; Bokemeyer C
    Oncol Rep; 2001; 8(6):1393-9. PubMed ID: 11605073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
    Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
    Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results.
    Rigacci L; Castagnoli A; Dini C; Carpaneto A; Matteini M; Alterini R; Carrai V; Nassi L; Bernardi F; Pieroni C; Bosi A
    Oncol Rep; 2005 Nov; 14(5):1209-14. PubMed ID: 16211287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
    Zhao J; Qiao W; Wang C; Wang T; Xing Y
    Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
    Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
    Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
    Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [18-FDG-PET-findings in children and adolescents with Hodgkin's disease: retrospective evaluation of the correlation to other imaging procedures in initial staging and to the predictive value of follow up examinations].
    Wickmann L; Lüders H; Dörffel W
    Klin Padiatr; 2003; 215(3):146-50. PubMed ID: 12778354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.
    Kostakoglu L; Goldsmith SJ; Leonard JP; Christos P; Furman RR; Atasever T; Chandramouly A; Verma S; Kothari P; Coleman M
    Cancer; 2006 Dec; 107(11):2678-87. PubMed ID: 17063502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.